Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock performance was -5.92% in last session and finished the day at $62.35. Traded volume was 400.60K shares in the last session and the average volume of the stock remained 275.43K shares. The beta of the stock remained. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) insider ownership is 2.40%.
Altisource Asset Management Corp (NASDAQ:AAMC) major shareholder Luxor Capital Group, Lp bought 2,371 shares of the stock in a transaction dated Friday, May 30th. The shares were purchased at an average cost of $964.35 per share, for a total transaction of $2,286,473.85. Altisource Asset Management Corp (NYSEMKT:AAMC) dropped -25.40 percent to $819.90 Monday on volume of 76.00K shares. The intra-day range of the stock was $819.90 to $1,037. Altisource Asset Management Corp (NYSEMKT:AAMC) has a market capitalization of $1.84billion.
OncoMed Pharmaceuticals Inc, (NASDAQ:OMED) a clinical stage company, reported on continued discussions begun last week with the US Food and Drug Administration (US FDA) regarding the company’s FZD8-Fc (OMP-54F28) Phase 1 programme. The FDA’s Division of Oncology Products 1 (DOP1) agreed with OncoMed’s voluntary halt, and informed the company that, as a formality, a partial clinical hold has been placed on Phase 1 clinical trials of FZD8-Fc. Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s stock on June 23, 2014 reported a decrease of -5.76% to the closing price of $23.09. Its fifty two weeks range is $12.07-$42.34. The total market capitalization recorded $682.54million. The overall volume in the last trading session was 190.30K shares. In its share capital, OMED has 29.56million outstanding shares.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Insider Scott Biller sold 2,004 shares of the company’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $50.05, for a total transaction of $100,300.20. Following the completion of the transaction, the insider now directly owns 30,000 shares of the company’s stock, valued at approximately $1,501,500. On Monday, shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped -11.07% to close the day at $44.02. Company return on investment (ROI) is -30.00% and its monthly performance is recorded as 31.32%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly revenue growth is 17.48%.